

ISSN (E): 2964-5565



JOURNAL OF SOCIETY MEDICINE

JOURNAL OF SOCIETY MEDICINE

Research & Review Articles on Diseases

Editor in Chief
Prof. dr. Aznan Lelo, PhD, SpFK.



PT COINREADS MEDIA PRIMA



Editorial Team

EDITOR-IN-CHIEF

Prof. dr. Aznan Lelo, PhD, Sp.FK

(Department of Pharmacology and Therapeutics, Universitas Sumatera Utara, Indonesia / The Flinders University South Australia: Bedford Park, Flinders Medical Centre, Adelaide, Bedford Park, Australia). ORCID ID: [0000-0002-3360-0120](#) | [Google Scholar](#) | Scopus ID: [6602966575](#) ;

[58199208100](#)

EDITORIAL BOARD

Prof. Dr. dr. H. Kurnia Fitri Jamil, M. Kes., Sp. PD., KPTI., FINASIM

(Department of Internal Medicine, Faculty of Medicine, Syiah Kuala University, Indonesia). ORCID ID: [0000-0002-3841-1951](#) |

[Google Scholar](#) | Scopus ID: [56156267700](#) (Co-Editor)

Dr. dr. Zinatul Hayati, M. Kes., Sp.MK

(Department of Microbiology and Immunology, Faculty of Medicine, Syiah Kuala University, **Indonesia**). ORCID ID:

[0000-0003-3775-0422](#) |

[Google Scholar](#) |

Scopus ID:

[36521039600](#) (Executive Manager)

dr. Agus Prima, M. Ked (An), Sp. An-TI

(Division of Anesthesiology and Intensive Care, National Center of Research and Education Institute (NCREI), **Indonesia**). ORCID ID:

[0000-0001-9351-6898](#) |

[Google Scholar](#) |

Scopus ID:

[57914390800](#)

(Director-in-Charge)

INTERNATIONAL EDITORIAL BOARD MEMBERS

Prof. dr. Rahmattullah Khan Bin Abdul Wahab Khan

(Department of Psychology and Counseling BS, MPsych(Clin), DPsych(Clin), UPSI, Malaysia). ORCID ID: [0000-0002-1198-977X](#) |

[Google Scholar](#) | Scopus ID: [7201674006](#) (Co-Editor and Ethics Manager)

Mohammed Habib, MD, PhD, FACC, FESC

(Assistant Professor, Istanbul Atlas University / School of Medicine, Head of Cardiology Department - Alshifa Hospital Gaza- Palestine).

ORCID ID: [0000-0001-7756-7249](#) |

[Google Scholar](#) |

Scopus ID:

[57437619000](#)

(Co-Editor)

Naoya Itoh, MD, PhD

(Division of Infectious Diseases, Aichi Cancer Center Hospital, Chikusa-ku, Nagoya, Japan), Scopus ID: [57188580125](#)

Synat Keam, MD

(School of Medicine, The University of Western Australia, Perth, Australia), Scopus ID: [57216501896](#)

Haypheng Te, MPH

(Siem Reap Provincial Health Department, Ministry of Health, Siem Reap, Cambodia), Scopus ID: [57216510747](#)

Abram L. Wagner, PhD

(Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, United States), Scopus ID: [56178049300](#)

REVIEWER

Dr. dr. Tasrif Hamdi, M. Ked (An), Sp.An, KMN (Department of Anesthesiology and Intensive Care, Faculty of Medicine, University of Sumatera Utara, **Indonesia**)

. ORCID ID: [0000-0002-5874-5991](#) | [Google Scholar](#) | Scopus ID:

[57222530737](#)

Dr. Jagat Narula (Professor of Medicine, Associate Dean for Global Health, Mount Sinai School of Medicine, St. Luke's-Roosevelt Hospital Center, **New York, USA**).

Scopus ID: [7006139754](#)

Dr. Graham R. Serjeant (Professor, Department of Hematology, Sickle Cell Trust Jamaica, The University of the West Indies, **Jamaica**).

Scopus ID: [16937253100](#)

Dr. dr. Bastian Lubis, M. Ked (An), Sp.An, KIC (Department of Anesthesiology and Intensive Care, Faculty of Medicine, University of Sumatera Utara, **Indonesia**)

. ORCID ID: [0000-0002-1839-4146](#) |

[Google Scholar](#) |

Scopus ID:

[57202790644](#)

Dr. A. Malhotra (Professor of Medicine, Director of Sleep Medicine, UC San Diego School of Medicine, **San Diego, USA**).

Scopus ID: [55844573100](#)

Dr. K.H. Mayer (Medical Research Director, Fenway Community Health, Fenway Institute, Boston, **Massachusetts, USA**).

Scopus ID: [7201681809](#)

dr. Putri Amelia M. Ked (Ped) Sp.A (K) (Department of Pediatric, Faculty of Medicine, University of Sumatera Utara, **Indonesia**)

. ORCID ID: [0000-0001-9941-2555](#) |

[Google Scholar](#) |

Scopus ID:

[56426988600](#)

Dr. dr. Fathia Meirina, M.Ked (Ped), Sp.A (Department of Pediatric, Faculty of Medicine, University of Sumatera Utara, **Indonesia**)

. ORCID ID: [0009-0000-4990-5423](#) |

[Google Scholar](#) |

Scopus ID:

[57195126024](#)

dr. Yudhisman Imran, Sp.N (Department of Neurology, Faculty of Medicine, Universitas Trisakti, **Indonesia**)

. ORCID ID: [0000-0003-4084-7364](#) |

[Google Scholar](#) |

Scopus ID:

[57216133814](#)

dr. Cut Rizka Rahmi, M.Sc (Health Professional Education, Taipei Medical University, **Taiwan**

/ Methodology for Clinical Research, Faculty of Medicine, Universitas Syiah Kuala, **Indonesia**). ORCID ID:

[0000-0001-7081-9749](#)

dr. Ade Oktiviyari, M.Sc (Microbiology, Griffith University, **Australia**)

. ORCID ID: [0000-0002-1392-200X](#) |

[Google Scholar](#) |

Scopus ID:

[57190306636](#)

dr. Dimas Arya Umara, Sp. JP-FIHA (Division of Cardiology and Vascular Medicine, National Center of Research and Education Institute (NCREI), **Indonesia**

). [Google Scholar](#) |

Scopus ID: [58149035400](#)

Dr. S.S. Abdool Karim (Director, CAPRISA, University of KwaZulu-Natal, Durban, Centre for the AIDS Programme of Research in South Africa. Congella, **South Africa**).

Scopus ID: [57159115100](#)

Dr. M. J. Albert, Professor (Department of Microbiology, Faculty of Medicine, Kuwait University, Safat, **Kuwait**).

Scopus ID: [7403276785](#)

Journal Menu

Editorial Board

Reviewer

Aims and Scope

Instructions for Author

Author Charges

Publication Ethics

Indexing and Abstracting

Editorial Process (Peer Review)

Plagiarism Policy

Copyright Terms

Privacy Statement

Archiving Policy

Informed Consent Policy

Open Access Policy

Submit Your Manuscript

Online submission · Open Access

Start submission →

DOCX

Article Template

Download & format your manuscript



Journal of Society Medicine

Research & Review Articles on Diseases · e-ISSN 2964-5565 · Open Access (CC BY 4.0)

INDEXED IN [Google Scholar](#) · [Garuda](#) · [Crossref](#)

JOURNAL INFORMATION

Aims and Scope

Editorial Board

Editorial Process (Peer Review)

Publication Ethics

Open Access Policy

Indexing and Abstracting

FOR AUTHORS

Instructions for Author

Author Charges

Plagiarism Policy

Copyright Terms

Privacy Statement

Archiving Policy

EDITORIAL OFFICE

National Center of Research and Education Institute (NCREI), Medan, Indonesia

chairman@jsocmed.com

Contact: dr. Agus Prima, M. Ked (An), Sp. An-TI

+62 812-6920-0232

ABOUT

Editor-in-Chief: Prof. dr. Aznan Lelo, PhD, Sp.FK.

Published by PT CoinReads Media Prima.



Vol. 5 No. 5 (2026): May

DOI: <https://doi.org/10.71197/jsocmed.v5i5>

Published: 2026-05-31

REVIEW ARTICLES

Curcumin in Sepsis: Anti-Inflammatory Mechanisms, Nano-Formulations, and Evidence from Preclinical and Early Clinical Studies

Yeni Puspawani, Gusbakti Rusip, Ali Napiah pp. 149-156

👁 517 views · · <https://doi.org/10.71197/jsocmed.v5i5.280>



PDF



HTML



XML

Flavonoids in Sepsis: Mechanistic Modulation of Inflammatory Pathways and Therapeutic Potential- A Systematic Review of Preclinical Studies

Yunita Dewani, Gusbakti Rusip , Boyke Marthin Simbolon pp. 157-172

👁 464 views · · <https://doi.org/10.71197/jsocmed.v5i5.255>



PDF



HTML



XML

ORIGINAL RESEARCH

Clinicopathological Profile of Colorectal Cancer Patients at Dr. Zainoel Abidin General Hospital, Banda Aceh, Indonesia: A Single-Center Retrospective Study

Nanda Subhan, Khalikul Razi , Maria Meildi, Darul Ilham , T. Fenny Novhera pp. 173-180

👁 654 views · · <https://doi.org/10.71197/jsocmed.v5i5.303>



PDF



HTML



XML

BRAF Mutation Status and Histopathological Differentiation Patterns in Non–Small Cell Lung Cancer: A Tertiary Referral Center Study in Indonesia

Lela Khaibirunna A.P, Noni Novisari Soeroso, Desfrina Kasuma, Putri Eyanoer pp. 181-187

👁 235 views · · <https://doi.org/10.71197/jsocmed.v5i5.281>



PDF



HTML



XML

Polycystic Ovary Syndrome (PCOS) as a Risk Factor for Preeclampsia and Cognitive Dysfunction

Ira Febri Yani, Irmiya Rachmiyani, Yudhisman Imran, Triasti Khusfiani, Dina Putri Nasution, Emad Yousif pp. 194-199

👁 677 views · · <https://doi.org/10.71197/jsocmed.v5i5.302>



PDF



HTML



XML

CASE REPORTS

The Role of Bronchoscopy as a Diagnostic and Therapeutic Modality in Critically Ill Patients with Respiratory Failure and Pneumonia in the Intensive Care Unit: A Descriptive Observational Study

Edi Darmawan, Rizki Taufiqurrahman, Sutan Syarif Muda Dalimunthe, Septian Adi Permana, Arie Zainul Fatoni, Teuku Yasir, Andriamuri Primaputra Lubis, Rommy Fransiscus Nadeak, Bastian Lubis pp. 188-193

👁 551 views · · <https://doi.org/10.71197/jsocmed.v5i5.284>



PDF



HTML



XML

Journal Menu

Editorial Board

Reviewer

Aims and Scope

Instructions for Author

Author Charges

Publication Ethics

Indexing and Abstracting

Editorial Process (Peer Review)

Plagiarism Policy

Copyright Terms

Privacy Statement

Archiving Policy

Informed Consent Policy

Open Access Policy

Submit Your Manuscript

Online submission · Open Access

Start submission →

DOCX

Article Template

Download & format your manuscript



JOURNAL INFORMATION

Aims and Scope

Editorial Board

Editorial Process (Peer Review)

Publication Ethics

Open Access Policy

Indexing and Abstracting

FOR AUTHORS

Instructions for Author

Author Charges

Plagiarism Policy

Copyright Terms

Privacy Statement

Archiving Policy

EDITORIAL OFFICE

National Center of Research and Education
Institute (NCREI), Medan, Indonesia

chairman@jsocmed.com

Contact: dr. Agus Prima, M. Ked (An), Sp. An-TI

+62 812-6920-0232

ABOUT

Editor-in-Chief: Prof. dr. Aznan Lelo, PhD, Sp.FK.

Published by PT CoinReads Media Prima.

Polycystic Ovary Syndrome (PCOS) as a Risk Factor for Preeclampsia and Cognitive Dysfunction

Ira Febri Yani ^{1*}, Irmia Rachmiyani ², Yudhisman Imran ³, Triasti Khusfiani ⁴, Dina Putri Nasution ⁵, Emad Yousif ⁶

¹ Department of Obstetrics and Gynecology, Hermina Hospital, Tangerang, Indonesia

² Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia

³ Department of Neurology, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia

⁴ Department of Pharmacology, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia

⁵ Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia

⁶ Department of Chemistry, Al-Nahrain University, Baghdad, Iraq

*Corresponding Author: Irmia Rachmiyani, E-mail: irmiya@trisakti.ac.id 

ARTICLE INFO

Article history:

Received

27 February 2026

Revised

28 April 2026

Accepted

31 May 2026

Manuscript ID: JSOCMED-27022026-55-6

Checked for Plagiarism: Yes

Language Editor: Rebecca

Editor-Chief: Prof. Aznan Lelo, PhD

Keywords

ABSTRACT

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. PCOS is associated with various metabolic disturbances, such as insulin resistance, obesity, dyslipidemia, and chronic inflammation, which may increase the risk of pregnancy complications, such as preeclampsia. In addition to increasing the risk of preeclampsia, PCOS has also been linked to a decline in cognitive function resulting from the effects of hyperandrogenism, insulin resistance, and systemic inflammation on neuronal function. Therefore, PCOS not only increases the risk of developing preeclampsia but may also play an indirect role in cognitive dysfunction. This narrative review discusses the role of PCOS as a risk factor for preeclampsia and cognitive impairment and the interconnected pathophysiological mechanisms linking these conditions.

Polycystic Ovary Syndrome (PCOS), Preeclampsia, Cognitive Function

How to cite: Yani IF, Rachmiyani I, Imran Y, Khusfiani T, Nasution DP, Yasir T, Lubis AP, Nadeak RF, Yousif E. Polycystic Ovary Syndrome (PCOS) as a Risk Factor for Preeclampsia and Cognitive Dysfunction. *Journal of Society Medicine*. 2026; 5 (5): 194-199. DOI: <https://doi.org/10.71197/jsocmed.v5i5.302>

INTRODUCTION

Polycystic ovary syndrome (PCOS) is an endocrine disorder that frequently occurs in women of reproductive age. According to the World Health Organization (2024), PCOS affects 6–13% of reproductive-aged women globally, with approximately 70% of cases remaining undiagnosed. The prevalence of PCOS in Indonesia has been reported to reach 45.7%, with cases predominantly occurring in the 26–30-year age group. Based on data from Statistics Indonesia (Badan Pusat Statistik, BPS), 12% of couples of reproductive age experience infertility, which is partly attributable to PCOS. Data from the Basic Health Research (Riskesdas) survey also recorded that 16% of adolescent girls who are overweight or obese contribute to the risk of PCOS [1].

The diagnosis of PCOS is most commonly established using the Rotterdam criteria, which require the presence of two of the following: oligo- or anovulation, clinical and/or biochemical signs of hyperandrogenism, or polycystic ovaries, together with the exclusion of other etiologies, such as congenital adrenal hyperplasia, androgen-secreting tumors, growth hormone-secreting pituitary tumors, and Cushing syndrome. PCOS presents with a wide variety of clinical phenotypes that may differ across ethnic groups [2]. PCOS is a heterogeneous endocrine disorder with diverse clinical manifestations and metabolic risks. According to the phenotypic classification proposed by the National Institutes of Health (NIH) in 2012, based

on the presence of hyperandrogenism (HA), ovulatory dysfunction (OD), and polycystic ovarian morphology (PCOM), PCOS is divided into four phenotypes (A–D). Phenotypes A and B are both characterized by hyperandrogenism and chronic oligo-anovulation (OA). Phenotype A, often referred to as classic PCOS, is additionally accompanied by polycystic ovarian morphology (PCOM); it is the most common phenotype, accounting for 50% of cases. Phenotype B is also known as hyperandrogenic anovulation. Phenotype C (ovulatory PCOS), although ovulation occurs, demonstrates metabolic abnormalities due to androgen excess. In contrast, phenotype D, which lacks hyperandrogenism, generally exhibits the mildest hormonal and metabolic profile, consisting of ovulatory dysfunction and polycystic ovarian morphology (PCOM) (non-hyperandrogenic PCOS) [3].

Clinically, PCOS presents a broad spectrum of symptoms, including menstrual irregularity, anovulation, subfertility or infertility, hyperandrogenism, and metabolic disturbances, such as insulin resistance (IR), dysglycemia, obesity, and dyslipidemia. These metabolic derangements not only contribute to the direct reproductive and endocrine manifestations of the syndrome but also predispose affected individuals to long-term risks, such as type 2 diabetes, metabolic syndrome, and cardiovascular disease. Phenotypes characterized by hyperandrogenism and OD (particularly phenotype A) tend to display more severe metabolic abnormalities and cardiovascular risk profiles, whereas non-hyperandrogenic phenotypes (e.g., phenotype D) may have a milder metabolic presentation [3]. In the neuropsychiatric domain, PCOS also exerts a considerable impact, such as cognitive dysfunction, anxiety, and depression [4]. Pregnant women with PCOS have an increased risk of pregnancy-related disorders, such as gestational diabetes mellitus (GDM), gestational hypertension, and preeclampsia in the second and third trimesters. In addition, there is an increased risk of preterm birth and low birth weight infants [5]. PCOS also causes further ovarian dysfunction that may result in anovulation and infertility [6]. The impact of PCOS may lead to long-term health problems, affecting not only reproductive health but also overall well-being, which can result in a reduced quality of life [4].

METHOD

This narrative review was prepared through a literature search of scientific publications relevant to polycystic ovary syndrome (PCOS), preeclampsia, and cognitive function. Electronic databases, including PubMed, Scopus, ScienceDirect, and Google Scholar, were used for the literature searches. The keywords used, applied individually and in combination with the Boolean operators “AND” and “OR,” included “polycystic ovary syndrome,” “PCOS,” “preeclampsia,” “cognitive function,” “cognitive impairment,” “insulin resistance,” “hyperandrogenism,” and “pregnancy outcomes.” The literature reviewed comprised original research articles, review articles, and cohort studies published predominantly between 2015 and 2026 in English and Indonesian. Articles were selected based on their relevance to the topic, namely, the relationship between PCOS, the risk of preeclampsia, and cognitive function, with priority given to the most recent and pertinent publications. Information obtained from the selected literature was subsequently analyzed narratively and synthesized to describe the interconnected pathophysiological mechanisms linking PCOS, preeclampsia, and cognitive dysfunction.

PCOS as a Risk Factor for Preeclampsia

Preeclampsia (PE) is a multisystem hypertensive disorder of pregnancy characterized by new-onset hypertension (blood pressure $\geq 140/90$ mmHg) after 20 weeks of gestation, accompanied by signs of maternal organ dysfunction (e.g., renal, hepatic, hematologic, or neurological involvement) and/or fetal growth restriction. Proteinuria (≥ 300 mg/24 hours) is a common but not essential criterion. PE affects approximately 2–8% of pregnancies worldwide, making it a leading cause of maternal and perinatal morbidity and mortality. The incidence of PE varies by region, with higher rates in low- and middle-income countries owing to limited access to prenatal care [7]. Currently, the most widely accepted theory regarding the development of PE is the two-stage theory. In this model, the first stage of the disease involves impaired placentation and reduced placental perfusion, whereas the second stage encompasses generalized maternal endothelial damage and dysfunction. This theory applies particularly to early-onset PE, which is characterized by placental

insufficiency and fetal growth restriction (FGR). However, late-onset PE, which is rarely associated with significant placental dysfunction, may have a somewhat different pathophysiological basis [8].

The second theory regarding the development of PE is cardiogenic theory. According to this model, the primary cause of the disease is preexisting cardiac dysfunction that is triggered or aggravated by pregnancy. This cardiac dysfunction subsequently leads to reduced placental perfusion and the characteristic clinical consequences observed in PE [8]. Many studies have shown that women with PCOS have an increased risk of developing preeclampsia. For example, in a prospective cohort study of patients with PCOS, a high body mass index (BMI) was found to be the strongest predictor of preeclampsia [9]. Furthermore, compared with pregnant women without PCOS, pregnant women with PCOS are more likely to be obese and nulliparous and to have received fertility treatment, all of which have been independently associated with the risk of preeclampsia [2]. Women with PCOS have an increased risk of pregnancy complications, including implantation failure, miscarriage, gestational diabetes, fetal growth restriction, preterm labor, and preeclampsia (PE). This may be attributable to specific vulnerabilities associated with PCOS before and during pregnancy, such as chronic systemic inflammation, insulin resistance, and hyperandrogenism, all of which have been linked to an increased risk of pregnancy complications. Giannakou et al. identified the strongest risk factors associated with PE, which include chronic kidney disease, PCOS, oocyte donation, obesity, and primiparity [10]. In addition to an increased risk of developing preeclampsia and various metabolic disorders, women with PCOS are also at risk of hypertension, leading to endothelial dysfunction that represents the early stage of the atherosclerotic process [7].

Normal placental development requires a complex network of bidirectional communication signals (cytokines, metabolites, hormones, and exosomes) between embryo-derived cells (trophoblasts and macrophages) and maternal-derived cells (endometrial glandular epithelium, stroma, macrophages, natural killer cells, dendritic cells, and T cells). Decades of epidemiological research have identified more than 70 maternal risk factors associated with the development of preeclampsia (PE). Pre-existing maternal pathophysiological factors play a role in the development of abnormal placentation and related complications, such as PE. Pre-existing maternal pathological features, such as chronic systemic inflammation, insulin resistance, and hyperandrogenemia, which occur in women with polycystic ovary syndrome (PCOS), can alter normal placental development, metabolism, and physiology at all stages of pregnancy [10]. Maternal angiogenic imbalance caused by placental antiangiogenic factors plays a central role in the systemic vascular dysfunction underlying PE. The severity of the maternal antiangiogenic state is closely correlated with maternal and perinatal outcomes. Assessment of angiogenic imbalance and several tests of vascular function have also emerged as means of detecting systemic vascular dysfunction during pregnancy [11]. Hyperandrogenism is associated with adverse pregnancy outcomes, such as PE, gestational diabetes, preterm birth, and small-for-gestational-age (SGA) infants. Women with PCOS who have high testosterone levels during pregnancy appear to be at a higher risk of PE. Early-onset preeclampsia and preeclampsia in women with small-for-gestational-age infants are considered subtypes of preeclampsia that have a more pronounced placental component than late-onset preeclampsia and preeclampsia in women without small-for-gestational-age infants. Placental studies have shown that the placentas of pregnant women with PCOS have altered histological structures, even in uncomplicated pregnancies. Placental lesions consist of microscopic changes in early trophoblast invasion and placentation [12].

PCOS and Cognitive Dysfunction

Cognitive function refers to a set of mental processes involved in learning, memory, attention, perception, language, intelligence, and reasoning. Cognitive function can be assessed in several ways. One way to assess cognitive function using a blood biomarker is through the measurement of brain-derived neurotrophic factor (BDNF) levels, an important protein that plays a significant role in enhancing the survival of synapses and neurons involved in memory and learning processes. BDNF is mainly expressed in the hippocampal and parahippocampal areas, which are crucial for cognitive tasks related to memory and learning [13,14]. In addition to BDNF levels, cognitive function can also be assessed using various questionnaire-based examinations. One frequently used questionnaire is the Montreal Cognitive Assessment (MoCA), which is generally used to screen for mild cognitive impairment (MCI). The domains assessed by the MoCA consist of attention and concentration, executive function, memory, language, visuoconstruction, conceptual thinking, calculation, and orientation skills [13]. Cognitive function may decline due to various independent predictor factors. One strategy to prevent cognitive impairment is to address modifiable risk factors. Factors that may drive a decline in cognitive function include brain injury, such as stroke, brain tumors, brain infections, and head injury. In addition to brain injury, aging, vascular disease (hypertension), metabolic disease (diabetes mellitus), and lifestyle factors such as physical inactivity, unhealthy diet, and smoking habits may also cause a decline in cognitive function [15]. One disease that carries cardiometabolic risk factors and also affects neuropsychiatric conditions is PCOS [16].

In PCOS, long-term complications may also occur in the form of metabolic disturbances and metabolic syndrome, which are commonly observed across various PCOS phenotypes. Metabolic syndrome may also affect cognitive performance. The role of insulin in the brains of healthy individuals includes central modulation of metabolism, enhancement or regulation of memory, and other cognitive and emotional functions. In PCOS, insulin resistance in the brain occurs, which can be defined as the failure of brain cells to respond to insulin, typically disrupting synaptic, metabolic, and immune responses. In addition to insulin resistance, a decline in cognitive function may also be caused by obesity, dyslipidemia, and disturbances in homocysteine metabolism, which may be the main factors in the development of cognitive impairment in women with PCOS, rather than androgens [4]. Obesity and being overweight are common problems among women with PCOS. Research has shown that obese women have substantially lower cognitive function and attention, indicating early impairment of cognitive function in obese women. The mechanism underlying the relationship between obesity and cognitive dysfunction remains unclear; however, it may be related to cerebral atrophy, cerebrovascular disturbances, and systemic and central inflammation. Some evidence supports the adverse impact of obesity on cognitive function in women; however, the longitudinal impact of obesity and weight gain in women with PCOS remains unclear [17].

A study conducted to investigate the effects of PCOS on brain activity and to explore the relationship between brain activity and sex hormone levels in women with PCOS showed that high luteinizing hormone (LH) levels may cause changes in the activity of brain regions responsible for visuospatial working memory, facial processing, and episodic memory [18]. In addition, higher free testosterone levels in women with PCOS have been associated with poorer cognitive function, particularly psychomotor speed and visuospatial learning [19]. Complications or diseases associated with metabolic syndrome, such as hypertension, may also be linked to cognitive impairment. High blood pressure is another complication of PCOS. Studies have shown that hypertension impairs the structure and function of cerebral blood vessels, leading to ischemic damage to the white matter involved in cognitive function, which may be related to Alzheimer pathology. There is strong evidence regarding the destructive effects of hypertension on cognitive function in middle-aged individuals [20,21]. The impact of PCOS on cognitive function has been examined by reviewing specific domains, finding evidence of mild but measurable deficits such as verbal fluency, working memory, visuospatial ability, and executive function compared with matched control groups. Several studies have reported reduced fluency associated with PCOS, whereas more studies have shown poorer memory findings in PCOS. Studies examining visuospatial cognition have shown mixed results, whereas executive function is impaired in PCOS. Some studies have specifically examined the impact of hyperandrogenism on cognition in PCOS and reported lower executive function associated with high androgen levels [16].

Existing research on cognition in women with PCOS has focused almost exclusively on women of reproductive age, typically ranging from late adolescence to the early 40s, and has not grouped or analyzed cognitive outcomes in perimenopausal subgroups. Estrogen is known to bind to neuroreceptors, with evidence of binding to extranuclear receptors within the hippocampus. In addition, estrogen signaling may have protective effects on central autonomic nuclei involved in cardiovascular regulation, an effect that is disrupted by the decline in estrogen during menopause. A recent study in women with PCOS, with a mean age of 54.7 years, showed lower performance in the cognitive domains of attention and cognitive control, verbal learning and memory, and category fluency compared to women without PCOS [16]. Women with PCOS exhibit distinct cognitive vulnerabilities, particularly in the executive, attention, language, and orientation domains. Cognitive dysfunction may be an underrecognized aspect of PCOS, warranting routine screening and future longitudinal studies. Recent attention has shifted toward the potential of PCOS to affect cognitive function. Emerging evidence suggests that women with PCOS may experience mild cognitive deficits across various domains, including memory, attention, executive function, and visuospatial skills. The etiology of these cognitive changes is not yet fully understood; however, hormonal, metabolic, and inflammatory factors are thought to play a role [22]. Another study showed that patients with PCOS had significantly poorer performance in the memory domain, as assessed by the Rey Auditory Verbal Learning Test (RAVLT), compared to the control group. According to the results of this test, immediate verbal memory was impaired in patients with PCOS. It has also been observed that recognition in the long-term delayed recall task was impaired in patients with PCOS [23].

Mechanism Linking PCOS – Preeclampsia – Cognitive Function

The relationship between PCOS, preeclampsia, and cognitive function can be explained through several interconnected pathophysiological mechanisms. PCOS is associated with insulin resistance, hypertension, dyslipidemia, infertility, and adverse pregnancy outcomes. Women with PCOS have an increased risk of miscarriage, hypertensive disorders during pregnancy, gestational diabetes, and preterm birth, and these risks vary depending on the PCOS phenotype. During pregnancy, normal placental development requires a complex network of bidirectional communication signals between

embryo- and maternal-derived cells. Pregnant women with PCOS experience chronic systemic inflammation, insulin resistance, and hyperandrogenemia. This chronic inflammation can disrupt trophoblast invasion and spiral artery remodeling, both of which play a role in the development of preeclampsia. In PCOS, long-term complications, such as metabolic syndrome, may occur, which can also affect cognitive performance. In pregnant women with PCOS, maternal angiogenic imbalance caused by placental antiangiogenic factors plays a central role in the systemic vascular dysfunction underlying preeclampsia. The release of antiangiogenic factors from the placenta can cause endothelial damage and impaired organ perfusion, including that of the brain. Damage to cerebral blood vessels resulting from endothelial dysfunction and chronic inflammation can affect neuronal function and lead to a decline in cognitive function.

CONCLUSION

Polycystic ovary syndrome (PCOS) is an endocrine disorder in reproductive-age women linked to metabolic complications, including type 2 diabetes mellitus, insulin resistance, cardiovascular disease, hypertension, dyslipidemia, infertility, and adverse pregnancy outcomes. Women with PCOS have increased preeclampsia risk, which can impair brain perfusion, damage neurons, and indirectly contribute to cognitive dysfunction.

DECLARATIONS

None

CONSENT FOR PUBLICATION

The authors agree to the publication of this article in the Journal of Society Medicine.

FUNDING

None

COMPETING INTERESTS

All authors have reviewed and approved the final version of the manuscript and have agreed to its publication in the Journal of Society Medicine.

AUTHORS' CONTRIBUTIONS

I.F.Y. conceived the study, conducted a literature review, and drafted the manuscript. I.R. supervised the study and revised the manuscript critically. Y.I., T.K., D.P.N., and E.Y. contributed to the data interpretation, manuscript review, and intellectual content. All the authors have read and approved the final manuscript.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia for their academic support in the preparation of this manuscript.

REFERENCE

1. Goni PA, Oktapiani DR, Shaumi NFN, Fadlilah F, Noufalwafiq MR, Ariyanto J. Clinical, Hormonal, and Psychosocial Aspects of Polycystic Ovary Syndrome in Adolescents: A Literature Review. J Malikussaleh Student Health Doctor. 2025;4(4):43-54.
2. Joshi A, Aluko A, Styer AK, Young BC, Johnson KM, Hacker MR, Et Al. PCOS And the Risk of Preeclampsia. Reprod Biomed Online. 2022;45(5):961-969.
3. Ma YC, Law KS, Wang WS, Chang HM. Phenotypic Variations in Polycystic Ovary Syndrome: Metabolic Risks and Emerging Biomarkers. J Endocrinol. 2025;267(1).
4. Naz MSG, Rahnamaei FA, Tehrani FR, Sayehmiri F, Ghasemi V, Banaei M, Et Al. Possible Cognition Changes in Women with Polycystic Ovary Syndrome: A Narrative Review. Obstet Gynecol Sci. 2023;66(5):347-363.
5. Tolstrup J, Jónsdóttir F, Ring CM, Andersen M, Elers J, Hedengran K, Et Al. Complications in Pregnant Women with Polycystic Ovary Syndrome. Ugeskr Laeger. 2016;178(12):V05150439.

6. Cunha A, Póvoa AM. Infertility Management in Women with Polycystic Ovary Syndrome: A Review. *Porto Biomed J.* 2021;6(1):E116.
7. Vakhariya SM, Shajahan A, Dube R, Kar SS, Goud BKM, Kar SS. Tracking Preeclampsia: The Role of Cerebral Biomarkers—A Narrative Review. *Int J Mol Sci.* 2026;27(2):806.
8. Kornacki J, Olejniczak O, Sibiak R, Gutaj P, Wender-Ozegowska E. Pathophysiology of Pre-Eclampsia—Two Theories of The Development of the Disease. *Int J Mol Sci.* 2023;25(1):307.
9. Foroozanfar F, Asemi Z, Bazarganipour F, Taghavi SA, Allan H, Aramesh S. Comparing Pregnancy, Childbirth, And Neonatal Outcomes in Women with Different Phenotypes of Polycystic Ovary Syndrome and Healthy Women: A Prospective Cohort Study. *Gynecol Endocrinol.* 2020;36(1):61-65.
10. Parker J, O'Brien CL, Yeoh C, Gersh FL, Brennecke S. Reducing the Risk of Pre-Eclampsia in Women with Polycystic Ovary Syndrome Using a Combination of Pregnancy Screening, Lifestyle, And Medical Management Strategies. *J Clin Med.* 2024;13(6):1774.
11. Tomimatsu T, Mimura K, Endo M, Kumasawa K, Kimura T. Pathophysiology of Preeclampsia: An Angiogenic Imbalance and Long-Lasting Systemic Vascular Dysfunction. *Hypertens Res.* 2017;40(4):305-310.
12. Valdimarsdottir R, Vanky E, Elenis E, Lindström L, Junus K, Jonsson M, Et Al. Polycystic Ovary Syndrome and Risk of Pre-Eclampsia: A National Register-Based Cohort Study. *BJOG.* 2024;131(7):985-995.
13. Adriani D, Amani P, Putri MA, Imran Y, Rachmiyani R, Fauzi A, Et Al. Memorizing Al-Quran Increases Serum BDNF Levels. *J Med Chem Sci.* 2025;8(4):339-344.
14. Adriani D, Imran Y, Mawi M, Amani P, Ilyas EI. Effect Of Brain Gym® Exercises on Cognitive Function and Brain-Derived Neurotrophic Factor Plasma Level in Elderly: A Randomized Controlled Trial. *Universa Med.* 2020;39(1):34-41.
15. Putri DM, Imran Y. Relationship Between Addiction to Online Video Games and Cognitive Function in Adolescents. *J Soc Med.* 2024;3(9):259-265.
16. Bernstein M, Dokras A, Flaherty C. Neuropsychological Profile of Polycystic Ovary Syndrome: Past, Present, And Future. *Fertil Steril.* 2025;124:948-955.
17. Cook RL, O'Dwyer NJ, Donges CE, Parker HM, Cheng HL, Steinbeck KS, Et Al. Relationship Between Obesity and Cognitive Function in Young Women: The Food, Mood and Mind Study. *J Obes.* 2017;2017:5923862.
18. Lai W, Li X, Zhu H, Zhu X, Tan H, Feng P, Et Al. Plasma Luteinizing Hormone Level Affects the Brain Activity of Patients with Polycystic Ovary Syndrome. *Psychoneuroendocrinology.* 2020;112:104535.
19. Sukhapure M, Eggleston K, Douglas K, Fenton A, Frampton C, Porter RJ. Free Testosterone Is Related to Aspects of Cognitive Function in Women with And Without Polycystic Ovary Syndrome. *Arch Womens Ment Health.* 2022;25:87-94.
20. Joham AE, Boyle JA, Zoungas S, Teede HJ. Hypertension In Reproductive-Aged Women with Polycystic Ovary Syndrome and Association with Obesity. *Am J Hypertens.* 2015;28:847–851.
21. Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB, Et Al. Impact of Hypertension on Cognitive Function: A Scientific Statement from The American Heart Association. *Hypertension.* 2016;68:E67-E94.
22. Dhumad MM, Hamdan FB, Al-Mayah QS. Cognitive Impairment and Associated Metabolic and Hormonal Factors in Women with Polycystic Ovarian Syndrome: A Montreal Cognitive Assessment-Based Case-Control Study. *Ital J Med.* 2025;19(4).
23. Sağsöz N, Koçak OM, Bender RA. Evaluation of Cognitive Functioning and Laterality in Women with Polycystic Ovary Syndrome. *Cam Sakura Med J.* 2025;5(1):9-16.
24. Fransisca A, Pison OM. Management of a Preeclampsia Patient with Diabetic Ketoacidosis and Acute Pulmonary Edema: A Case Report. *J Soc Med.* 2025;4(3):70-75.
25. Nasution ANZ, Rambe AS, Hutagalung HS. Relation between Parkinson's Disease Severity and Cognitive Function with Montreal Cognitive Assessment Indonesia. *J Soc Med.* 2023;2(9):296-301.

Turn it in Polycystic Ovary Syndrome (PCOS) as a Risk Factor

by FK

Submission date: 27-Aug-2026 09:10PM (UTC+0700)

Submission ID: 2652995823

File name: JSOCMED-27022026-55-6.pdf (1,014.28K)

Word count: 3974

Character count: 24010

Turn it in Polycystic Ovary Syndrome (PCOS) as a Risk Factor

ORIGINALITY REPORT

19%
SIMILARITY INDEX

13%
INTERNET SOURCES

11%
PUBLICATIONS

11%
STUDENT PAPERS

MATCH ALL SOURCES (ONLY SELECTED SOURCE PRINTED)

2%
★ Mayouri Sukhasure, Kate Eggleston, Anna Fenton, Christopher Frampton, Richard J Porter, Katie M Douglas. "Changes in Mood, Anxiety, and Cognition with Polycystic Ovary Syndrome Treatment: A Longitudinal, Naturalistic Study", Neuropsychiatric Disease and Treatment, 2022
Publication

Exclude quotes On
Exclude bibliography On

Exclude matches < 15 words

Polycystic Ovary Syndrome (PCOS) as a Risk Factor for Preeclampsia and Cognitive Dysfunction

Ira Febri Yani ^{1*}, Irmiya Rachmiyani ², Yudhisman Imran ³, Triasti Khusfiani ⁴, Dina Putri Nasution ⁵, Emad Yousif ⁶

¹ Department of Obstetrics and Gynecology, Hermina Hospital, Tangerang, Indonesia

² Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia

³ Department of Neurology, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia

⁴ Department of Pharmacology, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia

⁵ Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia

⁶ Department of Chemistry, Al-Nahrain University, Baghdad, Iraq

*Corresponding Author: Irmiya Rachmiyani, E-mail: irmiya@trisakti.ac.id

ARTICLE INFO

Article history:

Received

27 February 2026

Revised

28 April 2026

Accepted

31 May 2026

Manuscript ID: JSOCMED-27022026-55-6

Checked for Plagiarism: Yes

Language Editor: Rebecca

Editor-in-Chief: Prof. Aznan Lelo, PhD

Keywords

ABSTRACT

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. PCOS is associated with various metabolic disturbances, such as insulin resistance, obesity, dyslipidemia, and chronic inflammation, which may increase the risk of pregnancy complications, such as preeclampsia. In addition to increasing the risk of preeclampsia, PCOS has also been linked to a decline in cognitive function resulting from the effects of hyperandrogenism, insulin resistance, and systemic inflammation on neuronal function. Therefore, PCOS not only increases the risk of developing preeclampsia but may also play an indirect role in cognitive dysfunction. This narrative review discusses the role of PCOS as a risk factor for preeclampsia and cognitive impairment and the interconnected pathophysiological mechanisms linking these conditions.

Polycystic Ovary Syndrome (PCOS), Preeclampsia, Cognitive Function

How to cite: Yani IF, Rachmiyani I, Imran Y, Khusfiani T, Nasution DP, Yasir T, Lubis AP, Nadeak RF, Yousif E. Polycystic Ovary Syndrome (PCOS) as a Risk Factor for Preeclampsia and Cognitive Dysfunction. *Journal of Society Medicine*. 2026; 5 (5): 194-199. DOI: <https://doi.org/10.71197/jsocmed.v5i5.302>

INTRODUCTION

Polycystic ovary syndrome (PCOS) is an endocrine disorder that frequently occurs in women of reproductive age. According to the World Health Organization (2024), PCOS affects 6–13% of reproductive-aged women globally, with approximately 70% of cases remaining undiagnosed. The prevalence of PCOS in Indonesia has been reported to reach 45.7%, with cases predominantly occurring in the 26–30-year age group. Based on data from Statistics Indonesia (Badan Pusat Statistik, BPS), 12% of couples of reproductive age experience infertility, which is partly attributable to PCOS. Data from the Basic Health Research (Riskesdas) survey also recorded that 16% of adolescent girls who are overweight or obese contribute to the risk of PCOS [1].

The diagnosis of PCOS is most commonly established using the Rotterdam criteria, which require the presence of two of the following: oligo- or anovulation, clinical and/or biochemical signs of hyperandrogenism, or polycystic ovaries, together with the exclusion of other etiologies, such as congenital adrenal hyperplasia, androgen-secreting tumors, growth hormone-secreting pituitary tumors, and Cushing syndrome. PCOS presents with a wide variety of clinical phenotypes that may differ across ethnic groups [2]. PCOS is a heterogeneous endocrine disorder with diverse clinical manifestations and metabolic risks. According to the phenotypic classification proposed by the National Institutes of Health (NIH) in 2012, based

on the presence of hyperandrogenism (HA), ovulatory dysfunction (OD), and polycystic ovarian morphology (PCOM), PCOS is divided into four phenotypes (A–D). Phenotypes A and B are both characterized by hyperandrogenism and chronic oligo-anovulation (OA). Phenotype A, often referred to as classic PCOS, is additionally accompanied by polycystic ovarian morphology (PCOM); it is the most common phenotype, accounting for 50% of cases. Phenotype B is also known as hyperandrogenic anovulation. Phenotype C (ovulatory PCOS), although ovulation occurs, demonstrates metabolic abnormalities due to androgen excess. In contrast, phenotype D, which lacks hyperandrogenism, generally exhibits the mildest hormonal and metabolic profile, consisting of ovulatory dysfunction and polycystic ovarian morphology (PCOM) (non-hyperandrogenic PCOS) [3].

Clinically, PCOS presents a broad spectrum of symptoms, including menstrual irregularity, anovulation, subfertility or infertility, hyperandrogenism, and metabolic disturbances, such as insulin resistance (IR), dysglycemia, obesity, and dyslipidemia. These metabolic derangements not only contribute to the direct reproductive and endocrine manifestations of the syndrome but also predispose affected individuals to long-term risks, such as type 2 diabetes, metabolic syndrome, and cardiovascular disease. Phenotypes characterized by hyperandrogenism and OD (particularly phenotype A) tend to display more severe metabolic abnormalities and cardiovascular risk profiles, whereas non-hyperandrogenic phenotypes (e.g., phenotype D) may have a milder metabolic presentation [3]. In the neuropsychiatric domain, PCOS also exerts a considerable impact, such as cognitive dysfunction, anxiety, and depression [4]. Pregnant women with PCOS have an increased risk of pregnancy-related disorders, such as gestational diabetes mellitus (GDM), gestational hypertension, and preeclampsia in the second and third trimesters. In addition, there is an increased risk of preterm birth and low birth weight infants [5]. PCOS also causes further ovarian dysfunction that may result in anovulation and infertility [6]. The impact of PCOS may lead to long-term health problems, affecting not only reproductive health but also overall well-being, which can result in a reduced quality of life [4].

METHOD

This narrative review was prepared through a literature search of scientific publications relevant to polycystic ovary syndrome (PCOS), preeclampsia, and cognitive function. Electronic databases, including PubMed, Scopus, ScienceDirect, and Google Scholar, were used for the literature searches. The keywords used, applied individually and in combination with the Boolean operators “AND” and “OR,” included “polycystic ovary syndrome,” “PCOS,” “preeclampsia,” “cognitive function,” “cognitive impairment,” “insulin resistance,” “hyperandrogenism,” and “pregnancy outcomes.” The literature reviewed comprised original research articles, review articles, and cohort studies published predominantly between 2015 and 2026 in English and Indonesian. Articles were selected based on their relevance to the topic, namely, the relationship between PCOS, the risk of preeclampsia, and cognitive function, with priority given to the most recent and pertinent publications. Information obtained from the selected literature was subsequently analyzed narratively and synthesized to describe the interconnected pathophysiological mechanisms linking PCOS, preeclampsia, and cognitive dysfunction.

PCOS as a Risk Factor for Preeclampsia

Preeclampsia (PE) is a multisystem hypertensive disorder of pregnancy characterized by new-onset hypertension (blood pressure $\geq 140/90$ mmHg) after 20 weeks of gestation, accompanied by signs of maternal organ dysfunction (e.g., renal, hepatic, hematologic, or neurological involvement) and/or fetal growth restriction. Proteinuria (≥ 300 mg/24 hours) is a common but not essential criterion. PE affects approximately 2–8% of pregnancies worldwide, making it a leading cause of maternal and perinatal morbidity and mortality. The incidence of PE varies by region, with higher rates in low- and middle-income countries owing to limited access to prenatal care [7]. Currently, the most widely accepted theory regarding the development of PE is the two-stage theory. In this model, the first stage of the disease involves impaired placentation and reduced placental perfusion, whereas the second stage encompasses generalized maternal endothelial damage and dysfunction. This theory applies particularly to early-onset PE, which is characterized by placental

insufficiency and fetal growth restriction (FGR). However, late-onset PE, which is rarely associated with significant placental dysfunction, may have a somewhat different pathophysiological basis [8].

The second theory regarding the development of PE is cardiogenic theory. According to this model, the primary cause of the disease is preexisting cardiac dysfunction that is triggered or aggravated by pregnancy. This cardiac dysfunction subsequently leads to reduced placental perfusion and the characteristic clinical consequences observed in PE [8]. Many studies have shown that women with PCOS have an increased risk of developing preeclampsia. For example, in a prospective cohort study of patients with PCOS, a high body mass index (BMI) was found to be the strongest predictor of preeclampsia [9]. Furthermore, compared with pregnant women without PCOS, pregnant women with PCOS are more likely to be obese and nulliparous and to have received fertility treatment, all of which have been independently associated with the risk of preeclampsia [2]. Women with PCOS have an increased risk of pregnancy complications, including implantation failure, miscarriage, gestational diabetes, fetal growth restriction, preterm labor, and preeclampsia (PE). This may be attributable to specific vulnerabilities associated with PCOS before and during pregnancy, such as chronic systemic inflammation, insulin resistance, and hyperandrogenism, all of which have been linked to an increased risk of pregnancy complications. Giannakou et al. identified the strongest risk factors associated with PE, which include chronic kidney disease, PCOS, oocyte donation, obesity, and primiparity [10]. In addition to an increased risk of developing preeclampsia and various metabolic disorders, women with PCOS are also at risk of hypertension, leading to endothelial dysfunction that represents the early stage of the atherosclerotic process [7].

Normal placental development requires a complex network of bidirectional communication signals (cytokines, metabolites, hormones, and exosomes) between embryo-derived cells (trophoblasts and macrophages) and maternal-derived cells (endometrial glandular epithelium, stroma, macrophages, natural killer cells, dendritic cells, and T cells). Decades of epidemiological research have identified more than 70 maternal risk factors associated with the development of preeclampsia (PE). Pre-existing maternal pathophysiological factors play a role in the development of abnormal placentation and related complications, such as PE. Pre-existing maternal pathological features, such as chronic systemic inflammation, insulin resistance, and hyperandrogenemia, which occur in women with polycystic ovary syndrome (PCOS), can alter normal placental development, metabolism, and physiology at all stages of pregnancy [10]. Maternal angiogenic imbalance caused by placental antiangiogenic factors plays a central role in the systemic vascular dysfunction underlying PE. The severity of the maternal antiangiogenic state is closely correlated with maternal and perinatal outcomes. Assessment of angiogenic imbalance and several tests of vascular function have also emerged as means of detecting systemic vascular dysfunction during pregnancy [11]. Hyperandrogenism is associated with adverse pregnancy outcomes, such as PE, gestational diabetes, preterm birth, and small-for-gestational-age (SGA) infants. Women with PCOS who have high testosterone levels during pregnancy appear to be at a higher risk of PE. Early-onset preeclampsia and preeclampsia in women with small-for-gestational-age infants are considered subtypes of preeclampsia that have a more pronounced placental component than late-onset preeclampsia and preeclampsia in women without small-for-gestational-age infants. Placental studies have shown that the placentas of pregnant women with PCOS have altered histological structures, even in uncomplicated pregnancies. Placental lesions consist of microscopic changes in early trophoblast invasion and placentation [12].

PCOS and Cognitive Dysfunction

Cognitive function refers to a set of mental processes involved in learning, memory, attention, perception, language, intelligence, and reasoning. Cognitive function can be assessed in several ways. One way to assess cognitive function using a blood biomarker is through the measurement of brain-derived neurotrophic factor (BDNF) levels, an important protein that plays a significant role in enhancing the survival of synapses and neurons involved in memory and learning processes. BDNF is mainly expressed in the hippocampal and parahippocampal areas, which are crucial for cognitive tasks related to memory and learning [13,14]. In addition to BDNF levels, cognitive function can also be assessed using various questionnaire-based examinations. One frequently used questionnaire is the Montreal Cognitive Assessment (MoCA), which is generally used to screen for mild cognitive impairment (MCI). The domains assessed by the MoCA consist of attention and concentration, executive function, memory, language, visuoconstruction, conceptual thinking, calculation, and orientation skills [13]. Cognitive function may decline due to various independent predictor factors. One strategy to prevent cognitive impairment is to address modifiable risk factors. Factors that may drive a decline in cognitive function include brain injury, such as stroke, brain tumors, brain infections, and head injury. In addition to brain injury, aging, vascular disease (hypertension), metabolic disease (diabetes mellitus), and lifestyle factors such as physical inactivity, unhealthy diet, and smoking habits may also cause a decline in cognitive function [15]. One disease that carries cardiometabolic risk factors and also affects neuropsychiatric conditions is PCOS [16].

In PCOS, long-term complications may also occur in the form of metabolic disturbances and metabolic syndrome, which are commonly observed across various PCOS phenotypes. Metabolic syndrome may also affect cognitive performance. The role of insulin in the brains of healthy individuals includes central modulation of metabolism, enhancement or regulation of memory, and other cognitive and emotional functions. In PCOS, insulin resistance in the brain occurs, which can be defined as the failure of brain cells to respond to insulin, typically disrupting synaptic, metabolic, and immune responses. In addition to insulin resistance, a decline in cognitive function may also be caused by obesity, dyslipidemia, and disturbances in homocysteine metabolism, which may be the main factors in the development of cognitive impairment in women with PCOS, rather than androgens [4]. Obesity and being overweight are common problems among women with PCOS. Research has shown that obese women have substantially lower cognitive function and attention, indicating early impairment of cognitive function in obese women. The mechanism underlying the relationship between obesity and cognitive dysfunction remains unclear; however, it may be related to cerebral atrophy, cerebrovascular disturbances, and systemic and central inflammation. Some evidence supports the adverse impact of obesity on cognitive function in women; however, the longitudinal impact of obesity and weight gain in women with PCOS remains unclear [17].

A study conducted to investigate the effects of PCOS on brain activity and to explore the relationship between brain activity and sex hormone levels in women with PCOS showed that high luteinizing hormone (LH) levels may cause changes in the activity of brain regions responsible for visuospatial working memory, facial processing, and episodic memory [18]. In addition, higher free testosterone levels in women with PCOS have been associated with poorer cognitive function, particularly psychomotor speed and visuospatial learning [19]. Complications or diseases associated with metabolic syndrome, such as hypertension, may also be linked to cognitive impairment. High blood pressure is another complication of PCOS. Studies have shown that hypertension impairs the structure and function of cerebral blood vessels, leading to ischemic damage to the white matter involved in cognitive function, which may be related to Alzheimer pathology. There is strong evidence regarding the destructive effects of hypertension on cognitive function in middle-aged individuals [20,21]. The impact of PCOS on cognitive function has been examined by reviewing specific domains, finding evidence of mild but measurable deficits such as verbal fluency, working memory, visuospatial ability, and executive function compared with matched control groups. Several studies have reported reduced fluency associated with PCOS, whereas more studies have shown poorer memory findings in PCOS. Studies examining visuospatial cognition have shown mixed results, whereas executive function is impaired in PCOS. Some studies have specifically examined the impact of hyperandrogenism on cognition in PCOS and reported lower executive function associated with high androgen levels [16].

Existing research on cognition in women with PCOS has focused almost exclusively on women of reproductive age, typically ranging from late adolescence to the early 40s, and has not grouped or analyzed cognitive outcomes in perimenopausal subgroups. Estrogen is known to bind to neuroreceptors, with evidence of binding to extranuclear receptors within the hippocampus. In addition, estrogen signaling may have protective effects on central autonomic nuclei involved in cardiovascular regulation, an effect that is disrupted by the decline in estrogen during menopause. A recent study in women with PCOS, with a mean age of 54.7 years, showed lower performance in the cognitive domains of attention and cognitive control, verbal learning and memory, and category fluency compared to women without PCOS [16]. Women with PCOS exhibit distinct cognitive vulnerabilities, particularly in the executive, attention, language, and orientation domains. Cognitive dysfunction may be an underrecognized aspect of PCOS, warranting routine screening and future longitudinal studies. Recent attention has shifted toward the potential of PCOS to affect cognitive function. Emerging evidence suggests that women with PCOS may experience mild cognitive deficits across various domains, including memory, attention, executive function, and visuospatial skills. The etiology of these cognitive changes is not yet fully understood; however, hormonal, metabolic, and inflammatory factors are thought to play a role [22]. Another study showed that patients with PCOS had significantly poorer performance in the memory domain, as assessed by the Rey Auditory Verbal Learning Test (RAVLT), compared to the control group. According to the results of this test, immediate verbal memory was impaired in patients with PCOS. It has also been observed that recognition in the long-term delayed recall task was impaired in patients with PCOS [23].

Mechanism Linking PCOS – Preeclampsia – Cognitive Function

The relationship between PCOS, preeclampsia, and cognitive function can be explained through several interconnected pathophysiological mechanisms. PCOS is associated with insulin resistance, hypertension, dyslipidemia, infertility, and adverse pregnancy outcomes. Women with PCOS have an increased risk of miscarriage, hypertensive disorders during pregnancy, gestational diabetes, and preterm birth, and these risks vary depending on the PCOS phenotype. During pregnancy, normal placental development requires a complex network of bidirectional communication signals between

embryo- and maternal-derived cells. Pregnant women with PCOS experience chronic systemic inflammation, insulin resistance, and hyperandrogenemia. This chronic inflammation can disrupt trophoblast invasion and spiral artery remodeling, both of which play a role in the development of preeclampsia. In PCOS, long-term complications, such as metabolic syndrome, may occur, which can also affect cognitive performance. In pregnant women with PCOS, maternal angiogenic imbalance caused by placental antiangiogenic factors plays a central role in the systemic vascular dysfunction underlying preeclampsia. The release of antiangiogenic factors from the placenta can cause endothelial damage and impaired organ perfusion, including that of the brain. Damage to cerebral blood vessels resulting from endothelial dysfunction and chronic inflammation can affect neuronal function and lead to a decline in cognitive function.

CONCLUSION

Polycystic ovary syndrome (PCOS) is an endocrine disorder in reproductive-age women linked to metabolic complications, including type 2 diabetes mellitus, insulin resistance, cardiovascular disease, hypertension, dyslipidemia, infertility, and adverse pregnancy outcomes. Women with PCOS have increased preeclampsia risk, which can impair brain perfusion, damage neurons, and indirectly contribute to cognitive dysfunction.

DECLARATIONS

None

CONSENT FOR PUBLICATION

The authors agree to the publication of this article in the Journal of Society Medicine.

FUNDING

None

COMPETING INTERESTS

All authors have reviewed and approved the final version of the manuscript and have agreed to its publication in the Journal of Society Medicine.

AUTHORS' CONTRIBUTIONS

I.F.Y. conceived the study, conducted a literature review, and drafted the manuscript. I.R. supervised the study and revised the manuscript critically. Y.I., T.K., D.P.N., and E.Y. contributed to the data interpretation, manuscript review, and intellectual content. All the authors have read and approved the final manuscript.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia for their academic support in the preparation of this manuscript.

REFERENCE

1. Goni PA, Oktapiani DR, Shaumi NFN, Fadlilah F, Noufalwafiq MR, Ariyanto J. Clinical, Hormonal, and Psychosocial Aspects of Polycystic Ovary Syndrome in Adolescents: A Literature Review. J Malikussaleh Student Health Doctor. 2025;4(4):43-54.
2. Joshi A, Aluko A, Styer AK, Young BC, Johnson KM, Hacker MR, Et Al. PCOS And the Risk of Pre-Eclampsia. Reprod Biomed Online. 2022;45(5):961-969.
3. Ma YC, Law KS, Wang WS, Chang HM. Phenotypic Variations in Polycystic Ovary Syndrome: Metabolic Risks and Emerging Biomarkers. J Endocrinol. 2025;267(1).
4. Naz MSG, Rahnemaei FA, Tehrani FR, Sayehmiri F, Ghasemi V, Banaei M, Et Al. Possible Cognition Changes in Women with Polycystic Ovary Syndrome: A Narrative Review. Obstet Gynecol Sci. 2023;66(5):347-363.
5. Tolstrup J, Jónsdóttir F, Ring CM, Andersen M, Elers J, Hedengran K, Et Al. Complications in Pregnant Women with Polycystic Ovary Syndrome. Ugeskr Laeger. 2016;178(12):V05150439.

6. Cunha A, Póvoa AM. Infertility Management in Women with Polycystic Ovary Syndrome: A Review. *Porto Biomed J.* 2021;6(1):E116.
7. Vakhariya SM, Shajahan A, Dube R, Kar SS, Goud BKM, Kar SS. Tracking Preeclampsia: The Role of Cerebral Biomarkers—A Narrative Review. *Int J Mol Sci.* 2026;27(2):806.
8. Kornacki J, Olejniczak O, Sibiak R, Gutaj P, Wender-Ożegowska E. Pathophysiology of Pre-Eclampsia—Two Theories of The Development of the Disease. *Int J Mol Sci.* 2023;25(1):307.
9. Foroozanfard F, Asemi Z, Bazarganipour F, Taghavi SA, Allan H, Aramesh S. Comparing Pregnancy, Childbirth, And Neonatal Outcomes in Women with Different Phenotypes of Polycystic Ovary Syndrome and Healthy Women: A Prospective Cohort Study. *Gynecol Endocrinol.* 2020;36(1):61-65.
10. Parker J, O'Brien CL, Yeoh C, Gersh FL, Brennecke S. Reducing the Risk of Pre-Eclampsia in Women with Polycystic Ovary Syndrome Using a Combination of Pregnancy Screening, Lifestyle, And Medical Management Strategies. *J Clin Med.* 2024;13(6):1774.
11. Tomimatsu T, Mimura K, Endo M, Kumasawa K, Kimura T. Pathophysiology of Preeclampsia: An Angiogenic Imbalance and Long-Lasting Systemic Vascular Dysfunction. *Hypertens Res.* 2017;40(4):305-310.
12. Valdimarsdottir R, Vanky E, Elenis E, Lindström L, Junus K, Jonsson M, Et Al. Polycystic Ovary Syndrome and Risk of Pre-Eclampsia: A National Register-Based Cohort Study. *BJOG.* 2024;131(7):985-995.
13. Adriani D, Amani P, Putri MA, Imran Y, Rachmiyani R, Fauzi A, Et Al. Memorizing Al-Quran Increases Serum BDNF Levels. *J Med Chem Sci.* 2025;8(4):339-344.
14. Adriani D, Imran Y, Mawi M, Amani P, Ilyas EI. Effect Of Brain Gym® Exercises on Cognitive Function and Brain-Derived Neurotrophic Factor Plasma Level in Elderly: A Randomized Controlled Trial. *Universa Med.* 2020;39(1):34-41.
15. Putri DM, Imran Y. Relationship Between Addiction to Online Video Games and Cognitive Function in Adolescents. *J Soc Med.* 2024;3(9):259-265.
16. Bernstein M, Dokras A, Flaherty C. Neuropsychological Profile of Polycystic Ovary Syndrome: Past, Present, And Future. *Fertil Steril.* 2025;124:948-955.
17. Cook RL, O'Dwyer NJ, Donges CE, Parker HM, Cheng HL, Steinbeck KS, Et Al. Relationship Between Obesity and Cognitive Function in Young Women: The Food, Mood and Mind Study. *J Obes.* 2017;2017:5923862.
18. Lai W, Li X, Zhu H, Zhu X, Tan H, Feng P, Et Al. Plasma Luteinizing Hormone Level Affects the Brain Activity of Patients with Polycystic Ovary Syndrome. *Psychoneuroendocrinology.* 2020;112:104535.
19. Sukhapure M, Eggleston K, Douglas K, Fenton A, Frampton C, Porter RJ. Free Testosterone Is Related to Aspects of Cognitive Function in Women with And Without Polycystic Ovary Syndrome. *Arch Womens Ment Health.* 2022;25:87-94.
20. Joham AE, Boyle JA, Zoungas S, Teede HJ. Hypertension In Reproductive-Aged Women with Polycystic Ovary Syndrome and Association with Obesity. *Am J Hypertens.* 2015;28:847–851.
21. Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB, Et Al. Impact of Hypertension on Cognitive Function: A Scientific Statement from The American Heart Association. *Hypertension.* 2016;68:E67-E94.
22. Dhumad MM, Hamdan FB, Al-Mayah QS. Cognitive Impairment and Associated Metabolic and Hormonal Factors in Women with Polycystic Ovarian Syndrome: A Montreal Cognitive Assessment-Based Case-Control Study. *Ital J Med.* 2025;19(4).
23. Sağsöz N, Koçak OM, Bender RA. Evaluation of Cognitive Functioning and Laterality in Women with Polycystic Ovary Syndrome. *Cam Sakura Med J.* 2025;5(1):9-16.
24. Fransisca A, Pison OM. Management of a Preeclampsia Patient with Diabetic Ketoacidosis and Acute Pulmonary Edema: A Case Report. *J Soc Med.* 2025;4(3):70-75.
25. Nasution ANZ, Rambe AS, Hutagalung HS. Relation between Parkinson's Disease Severity and Cognitive Function with Montreal Cognitive Assessment Indonesia. *J Soc Med.* 2023;2(9):296-301.